Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of “Moderate Buy” from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-one research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have assigned a buy rating and one has assigned […]

Leave a Reply

Your email address will not be published.

Previous post GXO Logistics, Inc. (NYSE:GXO) Receives $69.38 Average PT from Brokerages
Next post Gold Royalty (NYSEAMERICAN:GROY) Stock Rating Upgraded by BMO Capital Markets